Cytori Therapeutics announces the issuance of key patents that strengthen its intellectual property portfolio in the US and Europe. Cytori now has 107 global patents issued and another 45 patent applications pending around the globe. Several of Cytori’s recently issued patents contain claims covering the use of Habeo Cell Therapy for patients with scleroderma affecting the hands.

On July 5, 2017 the European Patent Office (EPO) issued Patent No. 3046417, which claims the use of Adipose-Derived Regenerative Cells (ADRCs), including Cytori’s Habeo Cell Therapy for scleroderma, including treatment of Raynaud’s Phenomenon or suppression of pain from Raynaud’s Phenomenon. This patent has a term at least through 2034.

On April 19, 2017, the EPO issued Patent No. 1670315, which claims the use of ADRCs, including Cytori’s Habeo Cell Therapy, to treat vascular diseases, which are disorders that affect the blood carrying vessels of the body. Vascular disease is a very common complication in patients with scleroderma where it can contribute to digital ulcers and other problems. This patent has a term at least through 2024 and covers the use of Habeo Cell Therapy for vascular diseases, including but not limited to disease associated with scleroderma.

On December 6, 2016, the US Patent Office issued Patent No. 9511096, which claims the use of ADRCs, including Cytori Cell Therapy, to treat ischemic wounds. This patent has a term at least through December 2022 and covers the use of Habeo Cell Therapy for treatment of digital ulcers in scleroderma patients.

"Building on Cytori’s broad intellectual property portfolio continues to be a priority," said John D. Harris, vice president and general manager, Cell Therapy. "Our intellectual property strategy is to continue to strengthen the Cytori Cell Therapy platform  to help establish and maintain a sustainable competitive advantage. Our main focus is on the primary therapeutic targets of scleroderma and Raynaud’s Phenomenon, though we will continue to seek additional intellectual property in other therapeutic areas as well."